Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients
Current Oncology, 2021 Neurotrophic tyrosine receptor kinase gene fusions (NTRK) are oncogenic drivers present at a low frequency in most tumour types (80%) in a small number of rare tumours (e.g., infantile fibrosarcoma [IFS]) and considered mutually exclusive with other ...
Sébastien Perreault +10 more
doaj +1 more source
Head and Neck Mesenchymal Tumors with Kinase Fusions:A Report of 15 Cases with Emphasis on Wide Anatomic Distribution and Diverse Histologic Appearance [PDF]
, 2022 Mesenchymal tumors harboring various kinase fusions were recently recognized as emerging entities mainly in the soft tissues. We herein investigate the clinicopathologic and molecular characteristics of head and neck mesenchymal tumors harboring kinase ...
Agaram, Narasimhan P. +3 more
core +1 more source
Oncogenic driver mutations in lung cancer [PDF]
, 2013 published_or_final_versio
Lam, CLD, LUO, Y
core +1 more source
Cost-effectiveness of alternative NTRK testing strategies in cancer patients followed by histology-independent therapy with entrectinib:an analysis of three European countries [PDF]
, 2023 Aim: To explore variations in the cost-effectiveness of entrectinib across different testing strategies and settings. Methods: Four testing strategies where adult cancer patients received entrectinib if they tested positive for NTRK gene fusions compared
Huygens, Simone +8 more
core +1 more source
healthbook TIMES. Oncology Hematology, 2021 In May 2020, larotrectinib (Vitrakvi^®^) was approved as the first tumor-agnostic agent in Switzerland for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (*NTRK*) gene fusion.
Holger Moch +9 more
doaj +2 more sources
Phase 1 dose escalation study of the allosteric AKT inhibitor BAY 1125976 in advanced solid cancer-Lack of association between activating AKT mutation and AKT inhibition-derived efficacy [PDF]
, 2019 This open-label, phase I first-in-human study (NCT01915576) of BAY 1125976, a highly specific and potent allosteric inhibitor of AKT1/2, aimed to evaluate the safety, pharmacokinetics, and maximum tolerated dose of BAY 1125976 in patients with advanced ...
Boix, Oliver +14 more
core +3 more sources
Computational analysis reveals histotype-dependent molecular profile and actionable mutation effects across cancers [PDF]
, 2018 Background: Comprehensive mutational profiling data now available on all major cancers have led to proposals of novel molecular tumor classifications that modify or replace the established organ- and tissue-based tumor typing.
Heim, Daniel +4 more
core +6 more sources
NTRK3 overexpression in undifferentiated sarcomas with YWHAE and BCOR genetic alterations [PDF]
, 2020 The BCOR family of tumors includes a number of undifferentiated sarcomas, occurring in various age groups and anatomic sites, characterized by a spindle and round cell phenotype and diffuse immunoreactivity for BCOR.
Alaggio, Rita +8 more
core +1 more source
A systematic comparison of pan-Trk immunohistochemistry assays among multiple cancer types [PDF]
, 2023 AIMS NTRK rearranged tumours are rare but can be successfully treated using anti-TRK-targeted therapies, making NTRK testing important for treatment choices in patients with advanced cancers.
Haberecker, Martina +4 more
core +1 more source
Head &Neck, EarlyView.ABSTRACT Background Brain metastases (BM) of differentiated thyroid carcinoma (DTC) are associated with unfavorable prognosis. This study evaluated BM management strategies and patients' outcomes. Methods A retrospective review of patients diagnosed with DTC and BM at Tel Aviv Sourasky and Rabin Medical Centers between 1985 and 2024. Clinical features,
Liyona Kampel +9 more
wiley +1 more source